[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 32 of about 32
1. Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I: Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients. Cancer; 2008 Apr 1;112(7):1585-91
MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Significant clinical benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: retrospective analysis and identification of prognostic factors in 488 patients.
  • BACKGROUND: The efficacy of palliative chemotherapy was investigated in a large group of patients with advanced soft-tissue sarcomas (STS) treated on routine palliative protocols.
  • METHODS: Patients with STS who had first-line chemotherapy for advanced and/or metastatic disease between 1991 and 2005 were identified from the Royal Marsden Hospital's sarcoma database.
  • Patients with Ewing sarcoma, rhabdomyosarcoma, desmoplastic small round cell tumor, and gastrointestinal stromal tumors were excluded from the study.
  • The median age was 49 years and the majority (83%) received chemotherapy for metastatic disease.
  • The most common histologic subtypes were leiomyosarcoma (35%) synovial sarcoma (13%), liposarcoma (10%), and malignant fibrous histiocytoma (10%).
  • In all, 61% received single-agent chemotherapy, usually doxorubicin.
  • Patients treated with combination chemotherapy experienced longer OS than those treated with a single agent.
  • CONCLUSIONS: Palliative chemotherapy may be beneficial in approximately half of patients with advanced STS.
  • [MeSH-major] Sarcoma / drug therapy. Soft Tissue Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Antineoplastic Combined Chemotherapy Protocols. Bone Neoplasms / drug therapy. Bone Neoplasms / secondary. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Liver Neoplasms / drug therapy. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / secondary. Male. Middle Aged. Neoplasm Staging. Palliative Care. Prognosis. Prospective Studies. Retrospective Studies. Survival Rate

  • Genetic Alliance. consumer health - Soft tissue sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18278813.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


2. Miyake M, Fujimoto K, Tanaka M, Matsushita C, Tanaka N, Hirao Y: A case of small cell carcinoma of the kidney. Hinyokika Kiyo; 2007 Apr;53(4):235-40
Hazardous Substances Data Bank. ETOPOSIDE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] A case of small cell carcinoma of the kidney.
  • A 47-year-old man had a retroperitoneal tumor measuring 18 cm in maximum diameter of the left kidney that was diagnosed with computed tomography (CT)-guided needle biopsy as small cell carcinoma.
  • Microscopically, the tumor cells showed immunohistochemical reaction for neural cell adhesion molecule antibodies.
  • This patient with advanced renal small cell carcinoma and multiple metastatic lesions was treated with the first-line combination chemotherapy of cisplatin, etoposide and ifosphamide, which showed a partial response of primary renal tumor and a complete response of liver metastasis, and with the second-line chemotherapy of cisplatin and irinotecan, which showed a complete response of Virchow's nodal metastasis.
  • Thereafter, in spite of salvage chemotherapy of amurubicin hydrochloride for persistent and refractory renal small cell carcinoma, he died 32 months after the first presentation due to local progression.
  • However, combination chemotherapy of these anticancer agents made his prognosis more favorable than we expected before treatment.
  • The extrapulmonary small cell carcinomas are generally known to be more aggressive and malignant than the lung small cell carcinomas, and small cell carcinoma arising from the kidney is an extremely rare malignant neoplasm, with only 34 cases reported in the English or Japanese literature.
  • The prognosis of renal small cell carcinomas is currently limited as compared with the lung small cell carcinomas, and therefore a cumulative investigation of a larger number of cases treated with multidisciplinary modalities including combination chemotherapy is necessary.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Small Cell / drug therapy. Kidney Neoplasms / drug therapy. Lymph Nodes / pathology
  • [MeSH-minor] Camptothecin / administration & dosage. Camptothecin / analogs & derivatives. Cisplatin / administration & dosage. Drug Administration Schedule. Etoposide / administration & dosage. Humans. Lymphatic Metastasis. Male. Middle Aged. Piperidines / administration & dosage

  • MedlinePlus Health Information. consumer health - Kidney Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17515073.001).
  • [ISSN] 0018-1994
  • [Journal-full-title] Hinyokika kiyo. Acta urologica Japonica
  • [ISO-abbreviation] Hinyokika Kiyo
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Piperidines; 6PLQ3CP4P3 / Etoposide; 7673326042 / irinotecan; LHH887104B / ifoxetine; Q20Q21Q62J / Cisplatin; XT3Z54Z28A / Camptothecin
  •  go-up   go-down


3. Wu Z, Ma JY, Yang JJ, Zhao YF, Zhang SF: Primary small cell carcinoma of esophagus: report of 9 cases and review of literature. World J Gastroenterol; 2004 Dec 15;10(24):3680-2
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary small cell carcinoma of esophagus: report of 9 cases and review of literature.
  • AIM: To analyze the clinical manifestations, pathological features and treatment of primary small cell carcinoma (SCC) of the esophagus and to review the literature on this entity.
  • METHODS: The records of 9 patients with primary esophageal small cell carcinoma were examined and the demographic data, presenting symptoms, methods of tumor diagnosis, and types of treatment given, response to treatment, pathologic findings, and clinical outcome were reviewed.
  • Three of the nine resected specimens showed foci of squamous cell carcinoma in situ.
  • They received adjuvant systemic chemotherapy and local radiation therapy after discharge.
  • During follow-up, three patients developed multiple liver, brain, lung and bone metastases and died between 5 and 18 mo after the diagnosis.
  • Three patients developed widespread metastasis disease and died between 18 and 37 mo after the diagnosis.
  • CONCLUSION: Primary small cell carcinoma of the esophagus is a rare but very malignant tumor.
  • Radical resection combined with chemotherapy and radiotherapy is helpful in limited stage cases.
  • [MeSH-major] Carcinoma, Small Cell / pathology. Esophageal Neoplasms / pathology
  • [MeSH-minor] Aged. Female. Humans. Male. Middle Aged. Neoplasm Staging

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15534932.001).
  • [ISSN] 1007-9327
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] China
  • [Number-of-references] 18
  • [Other-IDs] NLM/ PMC4612018
  •  go-up   go-down


Advertisement
4. Thongprasert S, Cheewakriangkrai R, Napapan S: Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer. J Med Assoc Thai; 2002 Dec;85(12):1296-300
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel as second-line chemotherapy for advanced non-small cell lung cancer.
  • The purpose of this study was to evaluate the efficacy and safety of docetaxel as second-line chemotherapy for advanced non-small cell lung cancer (NSCLC).
  • Of 28 evaluable cases, 18 were adenocarcinoma, 3 squamous cell, 3 large cell and 4 undifferentiated carcinoma.
  • Five cases (19.2%) had liver metastases, 3 (11.5%) brain metastases, 6 (23%) bone metastases, and 17 (65.3%) metastatic nodules in the lung.
  • Besides chemotherapy, seven cases had received prior thoracic irradiation and two whole brain irradiation.
  • Two cases had prior surgery for malignant pleural effusion and one had thoracotomy for the resection of the primary tumor.
  • The time from the last dose of chemotherapy to the start of this study was less than 6 months in 20 cases, 6-12 months in 9, 12-24 months in 3 and more than 24 months in 2 cases.
  • One patient with initial small cell lung cancer had developed NSCLC before entering this study.
  • The median survival time was 23.8 weeks.
  • Docetaxel should be considered as second line chemotherapy in advanced NSCLC when primary chemotherapy including cisplatin and/or paclitaxel had failed.
  • [MeSH-major] Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Lung Neoplasms / drug therapy. Lung Neoplasms / pathology. Paclitaxel / administration & dosage. Paclitaxel / analogs & derivatives. Palliative Care / methods. Taxoids
  • [MeSH-minor] Adult. Aged. Dose-Response Relationship, Drug. Drug Administration Schedule. Female. Follow-Up Studies. Humans. Infusions, Intravenous. Male. Middle Aged. Neoplasm Staging. Survival Analysis. Treatment Outcome

  • Genetic Alliance. consumer health - Lung Cancer.
  • Genetic Alliance. consumer health - Non-small cell lung cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • MedlinePlus Health Information. consumer health - Palliative Care.
  • Hazardous Substances Data Bank. DOCETAXEL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12678167.001).
  • [ISSN] 0125-2208
  • [Journal-full-title] Journal of the Medical Association of Thailand = Chotmaihet thangphaet
  • [ISO-abbreviation] J Med Assoc Thai
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Thailand
  • [Chemical-registry-number] 0 / Taxoids; 15H5577CQD / docetaxel; P88XT4IS4D / Paclitaxel
  •  go-up   go-down


5. Wang L, Shen Y, Song R, Sun Y, Xu J, Xu Q: An anticancer effect of curcumin mediated by down-regulating phosphatase of regenerating liver-3 expression on highly metastatic melanoma cells. Mol Pharmacol; 2009 Dec;76(6):1238-45
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] An anticancer effect of curcumin mediated by down-regulating phosphatase of regenerating liver-3 expression on highly metastatic melanoma cells.
  • Phosphatase of regenerating liver-3 (PRL-3) has been suggested as a potential target for anticancer drugs based on its involvement in tumor metastasis.
  • However, little is known about a small-molecule inhibitor against PRL-3.
  • Cells with PRL-3 stably knocked down show less sensitivity to curcumin treatment, which reveals that PRL-3 is the much further upstream target of curcumin.
  • Curcumin treatment also remarkably prevented B16BL6 from invading the draining lymph nodes in the spontaneous metastatic tumor model, which is probably of relevance to PRL-3 down-regulation.
  • Our results reveal a novel capacity of curcumin to down-regulate oncogene PRL-3, raising its possibility in therapeutic regimen against malignant tumor.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Curcumin / pharmacology. Gene Expression Regulation, Neoplastic / drug effects. Immediate-Early Proteins / biosynthesis. Melanoma / enzymology. Protein Tyrosine Phosphatases / biosynthesis
  • [MeSH-minor] Animals. Breast Neoplasms / drug therapy. Breast Neoplasms / enzymology. Cell Line, Tumor. Down-Regulation / drug effects. Female. Humans. Male. Mice. Mice, Inbred C57BL. Neoplasm Metastasis. Neoplasms, Experimental. Prostatic Neoplasms / drug therapy. Prostatic Neoplasms / enzymology. Proto-Oncogene Proteins pp60(c-src) / antagonists & inhibitors. Reverse Transcriptase Polymerase Chain Reaction. STAT3 Transcription Factor / antagonists & inhibitors. Transcription, Genetic / drug effects. Tumor Suppressor Protein p53 / drug effects

  • MedlinePlus Health Information. consumer health - Melanoma.
  • Hazardous Substances Data Bank. CURCUMIN .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19779032.001).
  • [ISSN] 1521-0111
  • [Journal-full-title] Molecular pharmacology
  • [ISO-abbreviation] Mol. Pharmacol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Immediate-Early Proteins; 0 / Ptp4a3 protein, mouse; 0 / STAT3 Transcription Factor; 0 / Tumor Suppressor Protein p53; EC 2.7.10.2 / Proto-Oncogene Proteins pp60(c-src); EC 3.1.3.48 / Protein Tyrosine Phosphatases; IT942ZTH98 / Curcumin
  •  go-up   go-down


6. Wehbe H, Henson R, Lang M, Meng F, Patel T: Pifithrin-alpha enhances chemosensitivity by a p38 mitogen-activated protein kinase-dependent modulation of the eukaryotic initiation factor 4E in malignant cholangiocytes. J Pharmacol Exp Ther; 2006 Dec;319(3):1153-61
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pifithrin-alpha enhances chemosensitivity by a p38 mitogen-activated protein kinase-dependent modulation of the eukaryotic initiation factor 4E in malignant cholangiocytes.
  • Pifithrin-alpha is the lead compound for a novel group of small molecules that are being developed for use as anticancer agents.
  • The eukaryotic initiation factor 4E (eIF-4E) is overexpressed in many cancers, it can mediate sensitivity to therapy, and it may be regulated by p53.
  • We examined the utility of pifithrin-alpha as an adjunct to therapy for the treatment of human cholangiocarcinoma, a tumor that is highly refractory to therapy, and we assessed the involvement of p53-dependent eIF-4E regulation in cellular responses to pifithrin-alpha.
  • The expression of eIF-4E was increased in human cholangiocarcinomas compared with normal liver.
  • Sequencing analysis indicated the presence of a functionally inactivating p53 mutation in KMCH cells, and small interfering RNA to p53 did not modulate chemosensitization by pifithrin-alpha.
  • Moreover, modulation of eIF-4E is an attractive therapeutic target for intervention in cancer treatment.

  • MedlinePlus Health Information. consumer health - Bile Duct Cancer.
  • COS Scholar Universe. author profiles.
  • PhosphoSitePlus. gene/protein/disease-specific - PhosphoSitePlus® - comprehensive post-translational modification resource .
  • Hazardous Substances Data Bank. TOLUENE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16982703.001).
  • [ISSN] 0022-3565
  • [Journal-full-title] The Journal of pharmacology and experimental therapeutics
  • [ISO-abbreviation] J. Pharmacol. Exp. Ther.
  • [Language] ENG
  • [Grant] United States / NIDDK NIH HHS / DK / DK069370-01; United States / NIDDK NIH HHS / DK / R01 DK069370; United States / NIDDK NIH HHS / DK / DK069370; United States / NIDDK NIH HHS / DK / R01 DK069370-01
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Benzothiazoles; 0 / DNA, Neoplasm; 0 / Eukaryotic Initiation Factor-4E; 0 / Receptors, Aryl Hydrocarbon; 0 / pifithrin; 0W860991D6 / Deoxycytidine; 3FPU23BG52 / Toluene; B76N6SBZ8R / gemcitabine; EC 2.7.11.24 / p38 Mitogen-Activated Protein Kinases
  •  go-up   go-down


7. Kim L, Park YN, Kim SE, Noh TW, Park C: Teratoid hepatoblastoma: multidirectional differentiation of stem cell of the liver. Yonsei Med J; 2001 Aug;42(4):431-5
MedlinePlus Health Information. consumer health - Stem Cells.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Teratoid hepatoblastoma: multidirectional differentiation of stem cell of the liver.
  • Hepatoblastoma is the most common malignant hepatic neoplasm of childhood, showing a wide spectrum of epithelial and mesenchymal components.
  • Teratoid hepatoblastoma, which reveals multiple lines of tissue differentiation such as mucinous epithelium, melanin pigment, endocrine differentiation, glial and mesenchymal components, has rarely been observed.
  • She had been diagnosed with hepatoblastoma through percutaneous needle biopsy of the liver and treated with 10 chemotherapy cycles of epirubicin, VP-16 and cisplatin and with hepatic artery embolization.
  • There was extensive necrosis due to preoperative treatment.
  • These teratoid components were considered relatively resistant to preoperative chemotherapy, in contrast to extensive necrosis of both embryonal and fetal hepatocytes.
  • These teratoid features of hepatoblastoma are considered to be a multidirectional differentiation of the small epithelial cells or stem cells of the tumor.
  • [MeSH-major] Hepatoblastoma / pathology. Liver / pathology. Liver Neoplasms / pathology. Stem Cells / pathology
  • [MeSH-minor] Cell Differentiation. Female. Humans. Infant

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11519086.001).
  • [ISSN] 0513-5796
  • [Journal-full-title] Yonsei medical journal
  • [ISO-abbreviation] Yonsei Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Korea (South)
  •  go-up   go-down


8. Mingo L, Seguel F, Rollán V: Intraabdominal desmoplastic small round cell tumour. Pediatr Surg Int; 2005 Apr;21(4):279-81

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intraabdominal desmoplastic small round cell tumour.
  • Desmoplastic small round cell tumour (DSRCT) is an extremely rare neoplasm.
  • It is highly malignant, with only 29% of patients surviving up to 3 years.
  • Laboratory values were altered, and imaging showed multiples masses in the liver and retroperitoneum.
  • He was treated with chemotherapy but died of hepatic failure.
  • After treatment with chemotherapy, two operations were carried out to resect different intraabdominal masses.
  • The first patient died due to the advanced stage of the disease, and the second died after chemotherapy, peripheral blood stem transplantation, and multiple operations.
  • The occurrence of this type of tumour in the paediatric age group as well as its high malignancy is noteworthy.
  • Until more effective forms of treatment are found, we recommend treatment with chemotherapy, surgery, and radiotherapy, with close monitoring of the patient.
  • [MeSH-major] Abdominal Neoplasms / surgery. Carcinoma, Small Cell / surgery
  • [MeSH-minor] Child. Child, Preschool. Fatal Outcome. Humans. Inguinal Canal. Liver Neoplasms / diagnostic imaging. Male. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Am J Surg Pathol. 1998 Nov;22(11):1303-13 [9808123.001]
  • [Cites] Cancer. 1996 Aug 15;78(4):845-51 [8756380.001]
  • [Cites] Eur J Pediatr Surg. 2002 Oct;12(5):333-6 [12469262.001]
  • [Cites] J Surg Oncol. 1999 Aug;71(4):269-72 [10440769.001]
  • [Cites] J Pediatr Hematol Oncol. 2000 Sep-Oct;22(5):446-50 [11037858.001]
  • [Cites] Pediatr Hematol Oncol. 1996 Jan-Feb;13(1):95-9 [8718507.001]
  • [Cites] Ann Surg Oncol. 1998 Jul-Aug;5(5):416-22 [9718171.001]
  • [Cites] Pediatr Pathol. 1989;9(2):177-83 [2473463.001]
  • [Cites] Surg Oncol. 2000 Aug;9(2):77-81 [11094327.001]
  • (PMID = 15761710.001).
  • [ISSN] 0179-0358
  • [Journal-full-title] Pediatric surgery international
  • [ISO-abbreviation] Pediatr. Surg. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Germany
  •  go-up   go-down


9. Koschmieder S, Fauth F, Kriener S, Hoelzer D, Seipelt G: Effective treatment of simultaneous small cell lung cancer and B-cell lymphoma. Leuk Lymphoma; 2002 Mar;43(3):645-7
Genetic Alliance. consumer health - Lung Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Effective treatment of simultaneous small cell lung cancer and B-cell lymphoma.
  • Malignant lymphomas have been reported previously to coincide with adenocarcinomas of the stomach and, rarely, the kidney, breast, colon, liver, or lung.
  • Here, we describe the first case to our knowledge of a malignant lymphoma and an extensive disease small cell cancer of the lung.
  • A B-cell non-Hodgkin's lymphoma (NHL) was diagnosed from biopsies of the stomach and liver.
  • Further staging revealed a dense infiltration of the bone marrow by both a small cell lung cancer and a malignant lymphoma.
  • Both tumors responded well to chemotherapy.
  • This unique case report demonstrates that the simultaneous occurrence of small cell lung cancers and malignant lymphomas is extremely rare and may effectively be treated with chemotherapy.
  • [MeSH-major] Carcinoma, Small Cell / complications. Lymphoma, B-Cell / complications
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Bone Marrow / pathology. Humans. Liver / pathology. Male. Middle Aged. Neoplasm Invasiveness. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12002773.001).
  • [ISSN] 1042-8194
  • [Journal-full-title] Leukemia & lymphoma
  • [ISO-abbreviation] Leuk. Lymphoma
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] Switzerland
  •  go-up   go-down


10. Lieber J, Kirchner B, Eicher C, Warmann SW, Seitz G, Fuchs J, Armeanu-Ebinger S: Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells. Pediatr Blood Cancer; 2010 Dec 1;55(6):1089-95
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Inhibition of Bcl-2 and Bcl-X enhances chemotherapy sensitivity in hepatoblastoma cells.
  • BACKGROUND: An increased expression of anti-apoptotic proteins is regularly found in malignant cells, contributing to their clonal expansion by conferring an improved survival ability.
  • In Hepatoblastoma (HB) apoptosis regulation contributes to resistance and therapy failure, therefore we modulated apoptosis sensitivity of HB cells for an improved cytotoxic activity of commonly used drugs.
  • PROCEDURE: Apoptosis-related proteins were quantified in HB cells (HuH6 and HepT1) using protein assays.
  • Interaction of ABT-737, a small-molecule inhibitor of Bcl-2, Bcl-xL, and Bcl-W with cytotoxic drugs was monitored in a proliferation assay.
  • RESULTS: We found high levels of the anti-apoptotic protein Bcl-2 and Bcl-X as well as low levels of pro-apoptotic protein Bax and Bad in both HB cell lines.
  • ABT-737 also enhanced the cytotoxic effect of cisplatin (CDDP), doxorubicin (DOXO), etoposide and paclitaxel when used as combination therapy.
  • HuH6 expressed slightly higher pro-apoptotic and lower anti-apoptotic protein levels than HepT1, which may explain the stronger enhancement of cytostatic drug effects in HuH6 cells when treated in combination with ABT-737.
  • CONCLUSION: The observed anti-apoptotic phenotype in HB cell lines may contribute to resistance to cytotoxic drugs used in the standard treatment protocol of HB.
  • [MeSH-major] Apoptosis / drug effects. Biphenyl Compounds / pharmacology. Drug Resistance, Neoplasm. Hepatoblastoma / drug therapy. Liver Neoplasms / drug therapy. Nitrophenols / pharmacology. Proto-Oncogene Proteins c-bcl-2 / antagonists & inhibitors. Sulfonamides / pharmacology. bcl-X Protein / antagonists & inhibitors
  • [MeSH-minor] Antibiotics, Antineoplastic / pharmacology. Antineoplastic Agents / pharmacology. Blotting, Western. Cell Line, Tumor. Cisplatin / pharmacology. Doxorubicin / pharmacology. Humans. Piperazines / pharmacology

  • Genetic Alliance. consumer health - Hepatoblastoma.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • Hazardous Substances Data Bank. DOXORUBICIN .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20680965.001).
  • [ISSN] 1545-5017
  • [Journal-full-title] Pediatric blood & cancer
  • [ISO-abbreviation] Pediatr Blood Cancer
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / ABT-737; 0 / Antibiotics, Antineoplastic; 0 / Antineoplastic Agents; 0 / Biphenyl Compounds; 0 / Nitrophenols; 0 / Piperazines; 0 / Proto-Oncogene Proteins c-bcl-2; 0 / Sulfonamides; 0 / bcl-X Protein; 80168379AG / Doxorubicin; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


11. Petru E, Pasterk C, Reich O, Obermair A, Winter R, Breitenecker G: Small-cell carcinoma of the uterus and the vagina: experience with ten patients. Arch Gynecol Obstet; 2005 Apr;271(4):316-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Small-cell carcinoma of the uterus and the vagina: experience with ten patients.
  • BACKGROUND: Small cell carcinomas (small-CCs) of the uterine cervix are rare and highly malignant neoplasms.
  • Patients tend to develop distant metastasis early and thus are potential candidates for systemic therapy.
  • We reviewed the experience with small-CCs of the uterus and vagina at two Austrian University hospitals.
  • MATERIAL AND METHODS: Ten patients (median age, 50 years; range, 18-92) with small-CC of the cervix (n=7), uterine corpus (n=2), and the vagina (n=1) were treated at the two centers between 1988 and 1998.
  • Eight patients underwent radical surgery, 7 of whom also received chemotherapy.
  • Of the 7 patients with small-CC of the cervix only one, who had FIGO stage IIB disease and positive pelvic nodes, survived long-term (86 months) with no evidence of disease.
  • She had received six courses of dose-intensive platinum chemotherapy after radical surgery.
  • All three patients with small-CC of the uterine corpus or vagina developed recurrence within the first year after diagnosis.
  • Of the 7 patients who received chemotherapy, 5 developed progressive or recurrent disease in the paraaortic region (n=2), peritoneum (n=1), liver (n=1), or pelvis (n=1).
  • CONCLUSION: These results confirm the particularly unfavorable prognosis of patients with small-CC of the genital tract.
  • The optimal treatment for these patients most probably including concurrent chemo-radiotherapy remains to be defined.
  • [MeSH-major] Carcinoma, Small Cell / diagnosis. Carcinoma, Small Cell / therapy. Uterine Neoplasms / diagnosis. Uterine Neoplasms / therapy. Vaginal Neoplasms / diagnosis. Vaginal Neoplasms / therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Aged, 80 and over. Female. Gynecologic Surgical Procedures. Humans. Middle Aged. Neoplasm Recurrence, Local / diagnosis. Neoplasm Recurrence, Local / pathology. Radiotherapy. Retrospective Studies. Survival Analysis

  • Genetic Alliance. consumer health - TEN.
  • MedlinePlus Health Information. consumer health - Uterine Cancer.
  • MedlinePlus Health Information. consumer health - Vaginal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15197564.001).
  • [ISSN] 0932-0067
  • [Journal-full-title] Archives of gynecology and obstetrics
  • [ISO-abbreviation] Arch. Gynecol. Obstet.
  • [Language] eng
  • [Publication-type] Journal Article; Multicenter Study
  • [Publication-country] Germany
  •  go-up   go-down


12. Song Y, Wang LH, He J, Wang JW: [Treatment and prognosis of primary esophageal small cell carcinoma: a report of 151 cases]. Ai Zheng; 2009 Mar;28(3):303-7
MedlinePlus Health Information. consumer health - Esophageal Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Treatment and prognosis of primary esophageal small cell carcinoma: a report of 151 cases].
  • BACKGROUND AND OBJECTIVE: The treatment and prognosis of primary esophageal small cell carcinoma (PESC), an uncommon esophageal malignant tumor, have seldom been reported.
  • This study was to analyze the clinical characteristics, treatment and prognosis of PESC.
  • Patients received surgery, chemotherapy and/or radiotherapy.
  • The median survival time was longer in LD patients(12.3 months) than in those underwent local treatment alone (surgery or radiotherapy).
  • CONCLUSIONS: PESC is a malignant tumor with early metastasis and poor prognosis.
  • Combined therapy based on chemotherapy may improve the short term survival of PESC patients.
  • [MeSH-major] Carcinoma, Small Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Chemotherapy, Adjuvant. Female. Follow-Up Studies. Humans. Liver Neoplasms / secondary. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Neoplasm Staging. Neoplastic Cells, Circulating / pathology. Proportional Hazards Models. Radiotherapy, Adjuvant. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19619447.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Li Q, Feng FY, Chen Q, Jiao SC, Li F, Wang HQ, Huang WX, Ling CQ, Li MZ, Ren J, Zhang Y, Qin FZ, Zhou MZ, Zhu RZ: [Multicenter phase II clinical trial of uroacitides injection in the treatment for advanced malignant tumors]. Zhonghua Zhong Liu Za Zhi; 2008 Jul;30(7):534-7
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Multicenter phase II clinical trial of uroacitides injection in the treatment for advanced malignant tumors].
  • OBJECTIVE: To investigate the efficacy, safety and the life quality improvement of uroacitides injection in the treatment for patients with advanced malignant tumors.
  • METHODS: A total of 160 patients with advanced stage cancers were enrolled into this multicenter, open and non-randomized phase II clinical trial, including cancers of the lung (33 cases), liver (45 cases), breast (17 cases), esophagus (11 cases), stomach (18 cases), colon (19 cases), pancreas (3 cases) and kidney (4 cases), and glioma (10 cases).
  • [MeSH-major] Liver Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Methyltransferases / therapeutic use. Peptides / therapeutic use. Phenylacetates / therapeutic use
  • [MeSH-minor] Breast Neoplasms / blood. Breast Neoplasms / drug therapy. Breast Neoplasms / pathology. CA-19-9 Antigen / blood. Carcinoembryonic Antigen / blood. Carcinoma, Non-Small-Cell Lung / blood. Carcinoma, Non-Small-Cell Lung / drug therapy. Carcinoma, Non-Small-Cell Lung / pathology. Catheterization, Central Venous. Colorectal Neoplasms / blood. Colorectal Neoplasms / drug therapy. Colorectal Neoplasms / pathology. Humans. Nausea / chemically induced. Neoplasm Staging. Quality of Life. Remission Induction. Salvage Therapy. Treatment Outcome. Vomiting / chemically induced. alpha-Fetoproteins / metabolism

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19062723.001).
  • [ISSN] 0253-3766
  • [Journal-full-title] Zhonghua zhong liu za zhi [Chinese journal of oncology]
  • [ISO-abbreviation] Zhonghua Zhong Liu Za Zhi
  • [Language] chi
  • [Publication-type] Clinical Trial, Phase II; English Abstract; Journal Article; Multicenter Study
  • [Publication-country] China
  • [Chemical-registry-number] 0 / CA-19-9 Antigen; 0 / Carcinoembryonic Antigen; 0 / Peptides; 0 / Phenylacetates; 0 / alpha-Fetoproteins; 0 / cell differentiation agent II; EC 2.1.1.- / Methyltransferases
  •  go-up   go-down


14. Chatelain D, Maes C, Yzet T, Brevet M, Bounicaud D, Plachot JP, Verhaeghe P: [Primary hepatic lymphoma of MALT-type: a tumor that can simulate a liver metastasis]. Ann Chir; 2006 Feb;131(2):121-4
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Primary hepatic lymphoma of MALT-type: a tumor that can simulate a liver metastasis].
  • [Transliterated title] Le lymphome primitif hépatique de type MALT: une tumeur rare pouvant simuler une métastase hépatique.
  • We report a case of a 72 year-old woman with a past history of colonic adenocarcinoma who presented primary hepatic lymphoma of MALT-type.
  • She had been treated by chemotherapy for 6 months.
  • During the follow-up, the computed tomography-scan (CT-scan) revealed the presence of a not well-demarcated mass in segment III of the liver, measuring 4 cm in diameter.
  • Left lobectomy was performed with the diagnosis of liver metastasis of the colonic adenocarcinoma.
  • Surgical specimen showed a tumor composed of a dense infiltrate of small lymphocytes positive for B-cell markers on immunohistochemistry.
  • The patient is alive and free of disease 2 years after the diagnosis.
  • Primary hepatic lymphoma of MALT-type is a low-grade B cell lymphoma.
  • The pathogenesis is still unclear but half of the patients had a past history of chronic inflammatory liver disease (hepatitis B or C virus infection, ascaris infection, primary biliary cirrhosis) or malignant neoplasm.
  • This tumor has a good prognosis; it is usually limited to the liver and surgical resection cures the patient in most cases.
  • [MeSH-major] Liver Neoplasms / pathology. Liver Neoplasms / secondary. Lymphoma, B-Cell, Marginal Zone / pathology
  • [MeSH-minor] Aged. Diagnosis, Differential. Female. Humans

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16246295.001).
  • [ISSN] 0003-3944
  • [Journal-full-title] Annales de chirurgie
  • [ISO-abbreviation] Ann Chir
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article; Review
  • [Publication-country] France
  • [Number-of-references] 18
  •  go-up   go-down


15. Orlova A, Tran T, Widström C, Engfeldt T, Eriksson Karlström A, Tolmachev V: Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors. Int J Mol Med; 2007 Sep;20(3):397-404
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Pre-clinical evaluation of [111In]-benzyl-DOTA-Z(HER2:342), a potential agent for imaging of HER2 expression in malignant tumors.
  • Imaging of expression of human epidermal growth factor receptor type 2 (HER2) in breast carcinomas may help to select patients eligible for trastuzumab therapy.
  • The Affibody molecule Z(HER2:342) is a small (7-kDa) non-immunoglobulin affinity protein, which binds to HER2 with a picomolar affinity.
  • The specificity of 111In-benzyl-DOTA-Z(HER2:342) binding to HER2 was confirmed in vitro using HER2-expressing breast carcinoma BT474 and ovarian carcinoma SKOV-3 cell lines.
  • The use of benzyl-DTPA provided higher tumor-to-blood and tumor-to-liver ratios. gamma-camera imaging showed clear visualization of HER2-expressing xenografts using 111In-benzyl-DOTA-Z(HER2:342).
  • 111In-benzyl-DOTA-Z(HER2:342) has a potential for imaging of HER2 expression in malignant tumors.
  • [MeSH-minor] Animals. Cell Line, Tumor. Drug Evaluation, Preclinical. Female. Humans. Indium Radioisotopes / pharmacokinetics. Mice. Mice, Inbred BALB C. Mice, Nude. Neoplasm Transplantation. Radiopharmaceuticals / pharmacokinetics. Receptor, ErbB-2 / metabolism. Tissue Distribution. Transplantation, Heterologous


16. De Chiara A, De Rosa V, Lastoria S, Franco R, Botti G, Iaffaioli VR, Apice G: Primary gastrointestinal stromal tumor of the liver with lung metastases successfully treated with STI-571 (imatinib mesylate). Front Biosci; 2006;11:498-501
Hazardous Substances Data Bank. IMATINIB MESYLATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Primary gastrointestinal stromal tumor of the liver with lung metastases successfully treated with STI-571 (imatinib mesylate).
  • We report a case of a primary malignant GIST of the liver metastatic to the lung in a 37 years-old man.
  • The liver tumor showed histological feature of a GIST and expressed vimentin, and diffusely exhibited CD117.
  • One year after the resection of the liver mass, the patient developed multiple small lung metastases which completely disappeared with STI-571 (imatinib mesylate--Gleevec) therapy. C.T. or PET did not show any mass in the abdomen.
  • These findings suggest that the liver mass was a primary rather than a metastatic tumour.
  • They also support the hypothesis that GIST could originate from undifferentiated mesenchymal cells capable to differentiate toward a pacemaker cell phenotype, which are present in sites other than the G.I. tract.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Gastrointestinal Stromal Tumors / drug therapy. Gastrointestinal Stromal Tumors / pathology. Liver Neoplasms / drug therapy. Liver Neoplasms / pathology. Piperazines / therapeutic use. Pyrimidines / therapeutic use
  • [MeSH-minor] Adult. Benzamides. Cell Differentiation. Humans. Imatinib Mesylate. Male. Neoplasm Metastasis. Phenotype. Positron-Emission Tomography. Proto-Oncogene Proteins c-kit / biosynthesis. Tissue Distribution. Tomography, X-Ray Computed. Treatment Outcome. Vimentin / biosynthesis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16146747.001).
  • [ISSN] 1093-9946
  • [Journal-full-title] Frontiers in bioscience : a journal and virtual library
  • [ISO-abbreviation] Front. Biosci.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Benzamides; 0 / Piperazines; 0 / Pyrimidines; 0 / Vimentin; 8A1O1M485B / Imatinib Mesylate; EC 2.7.10.1 / Proto-Oncogene Proteins c-kit
  •  go-up   go-down


17. Sharykina NI, Bukhtiarova TA, Kudriavtseva IG, Pavlovskaia GP: [Cytostatic effects of bifolar and chlofiden. Effect on protein synthesis and cell cycle]. Ukr Biokhim Zh (1999); 2004 Jan-Feb;76(1):123-9

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Cytostatic effects of bifolar and chlofiden. Effect on protein synthesis and cell cycle].
  • Study of influence of new antitumor preparations bifolar and chlofiden on rat liver protein biosynthesis in vivo and on sarcoma-45 in vitro was carried out using labeled precursor 3H-leucine.
  • It was shown that the preparations inhibited protein synthesis in normal and malignant tissues.
  • [MeSH-major] Antineoplastic Agents / pharmacology. Ethylamines / pharmacology. Mitosis / drug effects. Neoplasm Proteins / biosynthesis. Phosphoramide Mustards / pharmacology. Protein Biosynthesis / drug effects. Sarcoma, Experimental / drug therapy
  • [MeSH-minor] Animals. Cell Line, Tumor. Intestine, Small / drug effects. Intestine, Small / metabolism. Intestine, Small / pathology. Liver / drug effects. Liver / metabolism. Liver / pathology. Mice. Neoplasm Transplantation. Rats. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15909427.001).
  • [Journal-full-title] Ukraïnsʹkyĭ biokhimichnyĭ z︠h︡urnal (1999 )
  • [ISO-abbreviation] Ukr Biokhim Zh (1999)
  • [Language] rus
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Ukraine
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Chlofiden; 0 / Ethylamines; 0 / Neoplasm Proteins; 0 / Phosphoramide Mustards; 1950-04-5 / Preparation F-11
  •  go-up   go-down


18. Sebastian M, Passlick B, Friccius-Quecke H, Jäger M, Lindhofer H, Kanniess F, Wiewrodt R, Thiel E, Buhl R, Schmittel A: Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study. Cancer Immunol Immunother; 2007 Oct;56(10):1637-44
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of non-small cell lung cancer patients with the trifunctional monoclonal antibody catumaxomab (anti-EpCAM x anti-CD3): a phase I study.
  • PURPOSE: Catumaxomab is a trifunctional monoclonal antibody with binding sites directed to human EpCAM and the human T cell antigen CD3 (anti-EpCAM x anti-CD3).
  • Catumaxomab demonstrated efficacy when administered intraperitoneally in patients with EpCAM positive malignant ascites from ovarian cancer in terms of tumor cell killing and reduction of ascites generation.
  • As EpCAM is also overexpressed in NSCLC, the present study was conducted in order to evaluate safety and tolerability of intravenous treatment with catumaxomab.
  • PATIENTS AND METHODS: UICC stage IB-IV NSCLC patients were eligible, if they had at least one prior therapy.
  • Elevated liver enzymes decreased to grade 2 within 3-7 days and were at baseline level within 14 days after infusion.
  • CONCLUSIONS: Five micrograms of catumaxomab with a pre-medication of 40 mg dexamethasone and antihistamines can be recommended as first dose for i.v. therapy consisting of multiple catumaxomab infusions for patients with NSCLC.
  • [MeSH-major] Antibodies, Bispecific / therapeutic use. Antibodies, Monoclonal / therapeutic use. Antineoplastic Agents / therapeutic use. Carcinoma, Non-Small-Cell Lung / drug therapy. Lung Neoplasms / drug therapy
  • [MeSH-minor] Adolescent. Adult. Aged. Animals. Antigens, CD3 / immunology. Antigens, Neoplasm / immunology. Cell Adhesion Molecules / immunology. Disease Progression. Female. Humans. Male. Mice. Middle Aged. Rats


19. Salamanca J, Nevado M, Martínez-González MA, Pérez-Espejo G, Pinedo F: Undifferentiated carcinoma of the jejunum with extensive rhabdoid features. Case report and review of the literature. APMIS; 2008 Oct;116(10):941-6
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant rhabdoid tumor, first described in the kidney of young infants, is a rare and highly aggressive neoplasm of controversial histogenesis that has been reported at many other sites, including the gastrointestinal tract.
  • However, malignant rhabdoid tumor of the small intestine is very rare, with only seven cases published to date.
  • The patient underwent partial jejunectomy and biopsy of a liver metastasis.
  • Immunohistochemically, the neoplasm coexpressed vimentin and epithelial antigens (AE1/AE3, Cam 5.2, CK34betaE12, CK19 and EMA), most of them showing a peculiar immunostaining pattern in relation to the globular inclusions.
  • The patient received postoperative chemotherapy but died 9 months after surgery.
  • As with tumors at other sites, recognition of rhabdoid morphology in small intestine neoplasms is of significance because the prognosis is extremely poor.
  • [MeSH-major] Carcinoma / pathology. Jejunal Neoplasms / pathology. Liver Neoplasms / secondary. Rhabdoid Tumor / pathology
  • [MeSH-minor] Aged. Anion Exchange Protein 1, Erythrocyte / analysis. Anion Exchange Protein 1, Erythrocyte / metabolism. Biomarkers / analysis. Biomarkers / metabolism. Biopsy. Cell Nucleolus / pathology. Fatal Outcome. Humans. Hyalin / metabolism. Immunohistochemistry. Inclusion Bodies / metabolism. Inclusion Bodies / pathology. Jejunum / metabolism. Jejunum / pathology. Keratins / analysis. Keratins / metabolism. Liver / pathology. Male. Neoplasm Proteins / analysis. Neoplasm Proteins / metabolism. Vimentin / analysis. Vimentin / metabolism

  • MedlinePlus Health Information. consumer health - Intestinal Cancer.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19132990.001).
  • [ISSN] 1600-0463
  • [Journal-full-title] APMIS : acta pathologica, microbiologica, et immunologica Scandinavica
  • [ISO-abbreviation] APMIS
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Denmark
  • [Chemical-registry-number] 0 / Anion Exchange Protein 1, Erythrocyte; 0 / Biomarkers; 0 / CAM 5.2 antigen; 0 / CK-34 beta E12; 0 / Neoplasm Proteins; 0 / Vimentin; 68238-35-7 / Keratins
  • [Number-of-references] 8
  •  go-up   go-down


20. Zhang PH, Tu ZG, Yang MQ, Huang WF, Zou L, Zhou YL: [Experimental research of targeting hTERT gene inhibited in hepatocellular carcinoma therapy by RNA interference]. Ai Zheng; 2004 Jun;23(6):619-25
NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Experimental research of targeting hTERT gene inhibited in hepatocellular carcinoma therapy by RNA interference].
  • BACKGROUND & OBJECTIVE: RNA interference (RNAi) is a new gene blocking technology that silences target gene at post-transcription level induced by the small interference RNA (siRNA).
  • RNAi has been demonstrated great prospect in gene functional research and gene therapy areas.
  • Nowadays, RNAi has been reported to be used to inhibit the expression of endogenous genes including cyclophilin, GAPDH, p53, and c-myc; and there were some progresses in the therapy of the diseases caused by AIDS and hepatitis viruses with RNAi.
  • However, hTERT gene, which was highly expressed in hepatocellular carcinoma and other malignant neoplasm, has not been researched by RNAi.
  • In present research, we utilized RNAi to inhibit hTERT gene expression in vitro and in vivo, investigated the feasibility and specificity of gene therapy for hepatocellular carcinoma.
  • METHODS: Small interference RNAs homologous to hTERT gene were designed,pTZU6+1-shRNA-hTERT vector was constructed and transfected into hepatocellular carcinoma SMMC-7721 cells and transplanted SMMC-7721 tumor in nude mice to induce RNAi.
  • The changes of hTERT gene expression and tumor cell proliferation in both siRNA treatment groups and control group were determined by flow cytometry, reverse transcription polymerase chain reaction (RT-PCR), immunochemistry in vitro and in vivo.
  • The inhibition rate of cell growth was 37.5% after pTZU6+1-shRNA-hTERT vector was transfected to hepatocellular carcinoma SMMC-7721 cells; the phase of cell cycle indicated the reduction of S phase, while G(1)/G(0) phase increased.
  • The tumor size reduced after treated with pTZU6+1-shRNA-hTERT vector in vivo; hTERT mRNA level decreased from 99.1% to 76.2%, and its protein expression decreased from 87.2% to 61.8% in siRNA treatment group.
  • CONCLUSION: RNAi inhibits the hTERT gene expression and proliferation of hepatocellular carcinoma SMMC-7721 cells with specificity, and is a possible new approach for neoplasm gene therapy.
  • [MeSH-major] Genetic Therapy. Liver Neoplasms / therapy. RNA Interference. RNA, Small Interfering / pharmacology. Telomerase / genetics
  • [MeSH-minor] Animals. Carcinoma, Hepatocellular / metabolism. Carcinoma, Hepatocellular / pathology. Carcinoma, Hepatocellular / therapy. Cell Division / drug effects. Cell Line, Tumor. DNA-Binding Proteins. Genetic Vectors. Humans. Male. Mice. Mice, Inbred BALB C. Mice, Nude. RNA, Messenger / genetics. Transfection

  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15191658.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] 0 / DNA-Binding Proteins; 0 / RNA, Messenger; 0 / RNA, Small Interfering; EC 2.7.7.49 / Telomerase
  •  go-up   go-down


21. Eilber FC, Eilber KS, Eilber FR: Retroperitoneal sarcomas. Curr Treat Options Oncol; 2000 Aug;1(3):274-8
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Imaging of the abdomen and pelvis by computed tomography (CT) provides both an imaging modality and a method by which to obtain tissue for diagnosis.
  • Because a histologic diagnosis is essential in treatment planning, adequate tissue can usually be obtained by a CT-guided core biopsy.
  • If the diagnosis is sarcoma, additional tests necessary for staging include plain chest radiography and evaluation of the liver by either CT scan or magnetic resonance imaging (MRI).
  • The treatment options for primary retroperitoneal sarcomas include chemotherapy, radiation therapy, surgery, or a combination of these modalities; therefore, a multidisciplinary group best manages treatment planning.
  • Primary radiation therapy for cure is seldom effective for retroperitoneal sarcomas but can provide palliation in select cases.
  • Systemic chemotherapy for chemosensitive lesions, such as poorly differentiated liposarcoma, malignant fibrous histiocytoma (MFH), synovial cell sarcoma, and primitive neuroectodermal tumors (PNET), can be useful when used in a neoadjuvant manner.
  • Consequently, surgical resection continues to be the mainstay of treatment for retroperitoneal sarcomas and requires en bloc resection of the primary tumor.
  • Frequently this includes adjacent organs such as colon, small bowel, kidney, adrenal, and pancreas.
  • Postoperative adjuvant therapy with chemotherapy or radiation has not been proven to be of any additional benefit.
  • Overall treatment results are predominantly influenced by tumor stage, grade, size, and margins of surgical resection.
  • [MeSH-major] Retroperitoneal Neoplasms / therapy. Sarcoma / therapy
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Biopsy / methods. Clinical Trials as Topic. Combined Modality Therapy. Humans. Neoplasm Recurrence, Local / pathology. Radiotherapy. Survival Rate

  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Am Coll Surg. 1996 Apr;182(4):329-39 [8605556.001]
  • [Cites] Surg Oncol. 1998 Jul-Aug;7(1-2):77-81 [10421510.001]
  • [Cites] J Clin Oncol. 1995 Jul;13(7):1600-8 [7541449.001]
  • [Cites] Cancer. 1999 Mar 1;85(5):1077-83 [10091791.001]
  • [Cites] Arch Surg. 1991 Mar;126(3):328-34 [1998475.001]
  • [Cites] J Clin Oncol. 1990 Jan;8(1):170-8 [2104923.001]
  • [Cites] Ann Surg. 1998 Sep;228(3):355-65 [9742918.001]
  • [Cites] J Clin Oncol. 1997 Aug;15(8):2832-9 [9256126.001]
  • [Cites] Cancer. 1977 May;39(5):1940-8 [858124.001]
  • [Cites] Ann Intern Med. 1982 Feb;96(2):133-9 [7059060.001]
  • [Cites] Cancer. 1994 May 15;73(10):2506-11 [8174046.001]
  • [Cites] Ann Surg. 1991 Jul;214(1):2-10 [2064467.001]
  • [Cites] Ann Surg. 1995 Feb;221(2):185-95 [7857146.001]
  • [Cites] Adv Surg. 1997;31:395-420 [9408503.001]
  • [Cites] Br J Surg. 1991 Aug;78(8):912-6 [1913104.001]
  • [Cites] Oncology (Williston Park). 1996 Dec;10(12):1867-72; discussion 1872-4 [8985970.001]
  • [Cites] Arch Surg. 1993 Apr;128(4):402-10 [8457152.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1994 Jul 30;29(5):1005-10 [8083069.001]
  • [Cites] Semin Oncol. 1997 Oct;24(5):526-33 [9344318.001]
  • (PMID = 12057171.001).
  • [ISSN] 1527-2729
  • [Journal-full-title] Current treatment options in oncology
  • [ISO-abbreviation] Curr Treat Options Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 21
  •  go-up   go-down


22. Yamamoto R, Hosokawa S, Yamatodani T, Morita S, Okamura J, Mineta H: [Eight cases of neuroendcrine carcinoma of the head and neck]. Nihon Jibiinkoka Gakkai Kaiho; 2008 Jul;111(7):517-22
Hazardous Substances Data Bank. EPIRUBICIN .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Small cell neuroendocrine carcinoma of the head and neck is rare, and diagnosis may be difficult.
  • We reported eight cases of stage IV small cell neuroendocrine carcinoma of the head and neck, all in men with a mean onset age of 62 years (range: 45 to 80 years).
  • Histological analysis by hematoxylin-eosin staining tentatively revealed malignant lymphoma and undifferentiated carcinoma in two cases each, while immunohistological and/or electron microscopy analysis confirmed histological diagnosis.
  • All were treated by chemotherapy (VP-16, CDDP) and seven cases with radiotherapy based on the schedule of small cell carcinoma of the lung and two cases with lesional resection.
  • Chemotherapy and radiotherapy were effective locally.
  • Five patients died of distant metastasis to the brain, bone, lung, liver, or skin within 12 months.
  • One is alive with liver metastasis.
  • Long-term survival thus requires the effective treatment of distant metastasis.
  • [MeSH-major] Carcinoma, Neuroendocrine / pathology. Carcinoma, Neuroendocrine / therapy. Head and Neck Neoplasms / pathology. Head and Neck Neoplasms / therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Biomarkers, Tumor / analysis. Cisplatin / administration & dosage. Combined Modality Therapy. Diagnosis, Differential. Epirubicin / administration & dosage. Humans. Immunohistochemistry. Magnetic Resonance Imaging. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 18697475.001).
  • [ISSN] 0030-6622
  • [Journal-full-title] Nihon Jibiinkoka Gakkai kaiho
  • [ISO-abbreviation] Nippon Jibiinkoka Gakkai Kaiho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 3Z8479ZZ5X / Epirubicin; Q20Q21Q62J / Cisplatin; PE regimen
  •  go-up   go-down


23. Cambien B, Karimdjee BF, Richard-Fiardo P, Bziouech H, Barthel R, Millet MA, Martini V, Birnbaum D, Scoazec JY, Abello J, Al Saati T, Johnson MG, Sullivan TJ, Medina JC, Collins TL, Schmid-Alliana A, Schmid-Antomarchi H: Organ-specific inhibition of metastatic colon carcinoma by CXCR3 antagonism. Br J Cancer; 2009 Jun 2;100(11):1755-64

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Liver and lung metastases are the predominant cause of colorectal cancer (CRC)-related mortality.
  • Recent research has indicated that CXCR3/chemokines interactions that orchestrate haematopoetic cell movement are implicated in the metastatic process of malignant tumours, including that of CRC cells to lymph nodes.
  • To date, however, the contribution of CXCR3 to liver and lung metastasis in CRC has not been addressed.
  • To determine whether CXCR3 receptors regulate malignancy-related properties of CRC cells, we have used CXCR3-expressing CRC cell lines of human (HT29 cells) and murine (C26 cells) origins that enable the development of liver and lung metastases when injected into immunodeficient and immunocompetent mice, respectively, and assessed the effect of CXCR3 blockade using AMG487, a small molecular weight antagonist.
  • In vivo, systemic CXCR3 antagonism by preventive or curative treatments with AMG487 markedly inhibited the implantation and the growth of human and mouse CRC cells within lung without affecting that in the liver.
  • In addition, we measured increased levels of CXCR3 and ligands expression within lung nodules compared with liver tumours.
  • Altogether, our findings indicate that activation of CXCR3 receptors by its cognate ligands facilitates the implantation and the progression of CRC cells within lung tissues and that inhibition of this axis decreases pulmonary metastasis of CRC in two murine tumour models.
  • [MeSH-minor] Animals. Antineoplastic Agents / therapeutic use. Cell Line, Tumor. Cell Movement. Humans. Ligands. Liver Neoplasms / drug therapy. Liver Neoplasms / metabolism. Liver Neoplasms / secondary. Lung Neoplasms / drug therapy. Lung Neoplasms / metabolism. Lung Neoplasms / secondary. Mice. Neoplasm Transplantation. Organ Specificity. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Blood. 2000 Jan 15;95(2):627-32 [10627472.001]
  • [Cites] Oncol Rep. 2003 Jul-Aug;10(4):909-13 [12792744.001]
  • [Cites] Nature. 2001 Mar 1;410(6824):50-6 [11242036.001]
  • [Cites] Lab Invest. 2001 Mar;81(3):409-18 [11310833.001]
  • [Cites] Arthritis Rheum. 2001 May;44(5):1022-32 [11352233.001]
  • [Cites] Cancer Res. 2002 Mar 15;62(6):1832-7 [11912162.001]
  • [Cites] J Immunol. 2003 Sep 15;171(6):2812-24 [12960302.001]
  • [Cites] Immunol Lett. 2004 Mar 29;92(1-2):171-8 [15081542.001]
  • [Cites] Cancer Res. 2004 Jun 1;64(11):4010-7 [15173015.001]
  • [Cites] Nat Rev Cancer. 2004 Jul;4(7):540-50 [15229479.001]
  • [Cites] J Exp Med. 1993 Sep 1;178(3):1057-65 [8350046.001]
  • [Cites] Proc Natl Acad Sci U S A. 1996 Nov 26;93(24):13791-6 [8943014.001]
  • [Cites] J Exp Med. 1996 Sep 1;184(3):963-9 [9064356.001]
  • [Cites] J Clin Invest. 1998 Feb 15;101(4):746-54 [9466968.001]
  • [Cites] Cancer Res. 2004 Dec 1;64(23):8604-12 [15574767.001]
  • [Cites] J Bone Miner Res. 2005 Feb;20(2):318-29 [15647826.001]
  • [Cites] Clin Cancer Res. 2005 Jan 15;11(2 Pt 1):490-7 [15701832.001]
  • [Cites] Blood. 2005 Mar 15;105(6):2428-35 [15536145.001]
  • [Cites] Clin Cancer Res. 2005 Mar 1;11(5):1743-50 [15755995.001]
  • [Cites] Life Sci. 2006 Mar 13;78(16):1784-93 [16263140.001]
  • [Cites] Cancer Res. 2006 Aug 1;66(15):7701-7 [16885372.001]
  • [Cites] Cancer Metastasis Rev. 2006 Sep;25(3):357-71 [17016763.001]
  • [Cites] Nat Rev Cancer. 2007 Feb;7(2):139-47 [17218951.001]
  • [Cites] Gut. 2007 Mar;56(3):365-72 [16870716.001]
  • [Cites] Cancer Res. 2007 Apr 1;67(7):3396-405 [17409450.001]
  • [Cites] J Immunother. 2007 Jul-Aug;30(5):490-8 [17589289.001]
  • [Cites] Oncogene. 2007 Jul 12;26(32):4679-88 [17297455.001]
  • [Cites] Cancer Sci. 2007 Nov;98(11):1652-8 [17894551.001]
  • [Cites] ChemMedChem. 2008 Jun;3(6):861-72 [18442035.001]
  • [Cites] Cancer Gene Ther. 2002 May;9(5):432-42 [11961666.001]
  • [Cites] Int J Cancer. 2002 May 1;99(1):149-53 [11948506.001]
  • [Cites] Cancer Res. 2002 May 1;62(9):2606-10 [11980656.001]
  • [Cites] J Invest Dermatol. 2002 Jun;118(6):915-22 [12060384.001]
  • [Cites] Nat Rev Cancer. 2002 Aug;2(8):563-72 [12154349.001]
  • [Cites] J Immunol. 2002 Nov 15;169(10):5546-54 [12421931.001]
  • [Cites] Hum Immunol. 2002 Dec;63(12):1164-71 [12480260.001]
  • [Cites] Hum Gene Ther. 2000 Jan 20;11(2):247-61 [10680839.001]
  • (PMID = 19436305.001).
  • [ISSN] 1532-1827
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Ligands; 0 / Receptors, CXCR3
  • [Other-IDs] NLM/ PMC2695685
  •  go-up   go-down


24. van Geer MA, Kuhlmann KF, Bakker CT, ten Kate FJ, Oude Elferink RP, Bosma PJ: Ex-vivo evaluation of gene therapy vectors in human pancreatic (cancer) tissue slices. World J Gastroenterol; 2009 Mar 21;15(11):1359-66
MedlinePlus Health Information. consumer health - Pancreatic Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Ex-vivo evaluation of gene therapy vectors in human pancreatic (cancer) tissue slices.
  • AIM: To culture human pancreatic tissue obtained from small resection specimens as a pre-clinical model for examining virus-host interactions.
  • METHODS: Human pancreatic tissue samples (malignant and normal) were obtained from surgical specimens and processed immediately to tissue slices.
  • Tissue slices were cultured ex vivo for 1-6 d in an incubator using 95% O(2).
  • RESULTS: With the Krumdieck tissue slicer, uniform slices could be generated from pancreatic tissue but only upon embedding the tissue in 3% low melting agarose.
  • Immunohistological examination showed the presence of all pancreatic cell types.
  • Pancreatic normal and cancer tissue slices could be cultured for up to 6 d, while retaining viability and a moderate to good morphology.
  • CONCLUSION: The presented system allows reproducible processing of minimal amounts of pancreatic tissue into slices uniform in size, suitable for pre-clinical evaluation of gene therapy vectors.
  • [MeSH-minor] Adenoviridae / genetics. Amylases / secretion. Animals. Cell Division. Disease Models, Animal. Gene Expression. Genes, Reporter. Genetic Therapy / methods. Genetic Vectors. Humans. Lentivirus / genetics. Mice. Mice, Nude. Neoplasm Transplantation. Plasmids. Transfection. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nat Med. 2000 Oct;6(10):1134-9 [11017145.001]
  • [Cites] Mol Ther. 2006 Jun;13(6):1085-92 [16581301.001]
  • [Cites] Gene Ther. 2001 Jan;8(2):89-98 [11313778.001]
  • [Cites] Gene Ther. 2001 Feb;8(4):308-15 [11313805.001]
  • [Cites] Gene Ther. 2001 May;8(9):730-5 [11406768.001]
  • [Cites] Gene Ther. 2001 Jul;8(13):969-76 [11438831.001]
  • [Cites] Curr Drug Metab. 2002 Feb;3(1):39-59 [11878310.001]
  • [Cites] J Hepatol. 2002 Apr;36(4):459-65 [11943415.001]
  • [Cites] Pancreas. 2002 Jul;25(1):71-7 [12131775.001]
  • [Cites] Mol Ther. 2002 Nov;6(5):609-14 [12409259.001]
  • [Cites] Clin Cancer Res. 2003 Feb;9(2):555-61 [12576418.001]
  • [Cites] Cancer Gene Ther. 2003 May;10(5):377-87 [12719707.001]
  • [Cites] Gastroenterology. 2003 Oct;125(4):1203-18 [14517802.001]
  • [Cites] Eur J Cancer. 2004 Mar;40(4):549-58 [14962722.001]
  • [Cites] Cancer Gene Ther. 2004 Apr;11(4):289-96 [14765131.001]
  • [Cites] Cancer Res. 1996 Dec 15;56(24):5713-9 [8971180.001]
  • [Cites] Nat Med. 1997 Jun;3(6):639-45 [9176490.001]
  • [Cites] Gene Ther. 1999 Sep;6(9):1520-35 [10490761.001]
  • [Cites] Hum Gene Ther. 2004 Nov;15(11):1034-44 [15610604.001]
  • [Cites] Clin Cancer Res. 2004 Dec 15;10(24):8697-703 [15623655.001]
  • [Cites] Clin Cancer Res. 2005 Jan 1;11(1):351-60 [15671566.001]
  • [Cites] Pancreas. 2005 Mar;30(2):148-57 [15714137.001]
  • [Cites] Cancer Res. 2007 Jan 15;67(2):429-32 [17234747.001]
  • [Cites] J Clin Oncol. 2007 Jun 20;25(18):2607-15 [17577041.001]
  • [Cites] Cell Biochem Biophys. 2007;48(2-3):183-90 [17709888.001]
  • [Cites] World J Gastroenterol. 2007 Sep 7;13(33):4423-30 [17724796.001]
  • [Cites] J Gene Med. 2006 Jan;8(1):35-41 [16044485.001]
  • [Cites] J Virol Methods. 2001 Apr;93(1-2):181-8 [11311357.001]
  • (PMID = 19294766.001).
  • [ISSN] 2219-2840
  • [Journal-full-title] World journal of gastroenterology
  • [ISO-abbreviation] World J. Gastroenterol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] China
  • [Chemical-registry-number] EC 3.2.1.- / Amylases
  • [Other-IDs] NLM/ PMC2658838
  •  go-up   go-down


25. Hornick JL, Jaffe ES, Fletcher CD: Extranodal histiocytic sarcoma: clinicopathologic analysis of 14 cases of a rare epithelioid malignancy. Am J Surg Pathol; 2004 Sep;28(9):1133-44
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Histiocytic sarcoma is a rare malignant neoplasm that occurs in lymph nodes, skin, and the gastrointestinal tract.
  • Only small numbers of bona fide examples exist in the world literature; cases arising primarily at extranodal sites are not well described and often seem to go unrecognized.
  • Seven tumors arose in soft tissue (6 lower limb; 1 upper limb), 5 in the gastrointestinal tract (1 involving both stomach and colon, 1 ileum, 2 rectum, 1 anus), 1 in the nasal cavity, and 1 in the lung.
  • Three gastrointestinal tract tumors also involved regional lymph nodes, and 1 involved the liver.
  • Six patients were treated with postoperative radiation and 7 with chemotherapy (CHOP or ProMACE-MOPP).
  • Two tumors recurred locally, and 5 patients developed distant spread: 3 to lymph nodes, 1 to lung, and 1 to bone.
  • At the last follow-up, 2 patients have died of disseminated disease, 4 and 5 months following initial diagnosis.
  • Histiocytic sarcoma may arise primarily in soft tissue and shows reproducible histologic features, including abundant eosinophilic cytoplasm and a prominent inflammatory infiltrate.
  • Metastatic carcinoma, metastatic melanoma, and large cell non-Hodgkin lymphomas should be excluded by immunohistochemistry.

  • Genetic Alliance. consumer health - Epithelioid Sarcoma.
  • MedlinePlus Health Information. consumer health - Soft Tissue Sarcoma.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15316312.001).
  • [ISSN] 0147-5185
  • [Journal-full-title] The American journal of surgical pathology
  • [ISO-abbreviation] Am. J. Surg. Pathol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


26. Lim YP, Wong CY, Ooi LL, Druker BJ, Epstein RJ: Selective tyrosine hyperphosphorylation of cytoskeletal and stress proteins in primary human breast cancers: implications for adjuvant use of kinase-inhibitory drugs. Clin Cancer Res; 2004 Jun 15;10(12 Pt 1):3980-7
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Selective tyrosine hyperphosphorylation of cytoskeletal and stress proteins in primary human breast cancers: implications for adjuvant use of kinase-inhibitory drugs.
  • PURPOSE: Small-molecule growth factor receptor inhibitors block cell growth in vitro and downstream signaling in vivo, but controlled trials in patients with advanced solid tumors have yielded disappointing response rates.
  • EXPERIMENTAL DESIGN: Immunoaffinity chromatography, two-dimensional electrophoresis, and antiphosphotyrosine immunoblotting were combined with mass spectrometry to determine the phosphoproteomic signatures of 40 matched normal and malignant tissues from patients with breast or liver cancer.
  • RESULTS: Patterns of tyrosine-phosphorylated proteins are similar among normal tissues of the same origin but vary markedly between different tissues.
  • Primary breast tumors exhibit a strikingly homogeneous tyrosine phosphorylation profile, whereas liver cancers display greater phosphoproteomic diversity.
  • CONCLUSIONS: Identification of cytoskeletal and stress proteins as the most abundant tyrosine phosphoproteins in breast tumors implicates these molecules, rather than promitogenic effectors, as the prime stoichiometric substrates for kinase-inhibitory anticancer drugs in vivo.
  • Because phosphorylated cytoskeletal proteins and chaperones mediate cell motility and apoptotic resistance, respectively, these data raise the intriguing possibility that small-molecule tyrosine kinase inhibitors may be of greatest value either as adjuvant antimetastatic/-invasive drugs or as chemo-/radiosensitizers.
  • [MeSH-major] Breast Neoplasms / drug therapy. Breast Neoplasms / metabolism. Chemotherapy, Adjuvant / methods. Cytoskeleton / metabolism. Tyrosine / chemistry
  • [MeSH-minor] Animals. Apoptosis. Cell Line, Tumor. Chromatography / methods. Electrophoresis, Gel, Two-Dimensional / methods. Heat-Shock Proteins / chemistry. Humans. Immunoblotting. Ligands. Male. Mass Spectrometry. Mice. Mice, Inbred BALB C. Neoplasm Metastasis. Neoplasms / metabolism. Phosphoproteins / chemistry. Phosphorylation. Phosphotyrosine / chemistry. Signal Transduction

  • MedlinePlus Health Information. consumer health - Breast Cancer.
  • Hazardous Substances Data Bank. L-TYROSINE .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15217928.001).
  • [ISSN] 1078-0432
  • [Journal-full-title] Clinical cancer research : an official journal of the American Association for Cancer Research
  • [ISO-abbreviation] Clin. Cancer Res.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Heat-Shock Proteins; 0 / Ligands; 0 / Phosphoproteins; 21820-51-9 / Phosphotyrosine; 42HK56048U / Tyrosine
  •  go-up   go-down


27. Kurita S, Higuchi H, Saito Y, Nakamoto N, Takaishi H, Tada S, Saito H, Gores GJ, Hibi T: DNMT1 and DNMT3b silencing sensitizes human hepatoma cells to TRAIL-mediated apoptosis via up-regulation of TRAIL-R2/DR5 and caspase-8. Cancer Sci; 2010 Jun;101(6):1431-9
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • DNA methyltransferases (DNMTs) are hypothesized to mediate cellular DNA methylation status and gene expression during mammalian development and in malignant diseases.
  • In this study, we examined the role of DNA methyltransferase 1 (DNMT1) and DNMT3b in cell proliferation and survival of hepatocellular carcinoma (HCC) cells.
  • Gene silencing of both DNMT1 and DNMT3b by targeted siRNA knockdown reduces cell proliferation and sensitizes the cells to tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated cell death.
  • In conclusion, our data suggest that DNA methylation of specific genomic regions maintained by DNMT1 and DNMT3b plays a critical role in survival of HCC cells, and a simultaneous knockdown of both DNMT1 and DNMT3b may be a novel anticancer strategy for the treatment of HCC.
  • [MeSH-major] Apoptosis. Carcinoma, Hepatocellular / drug therapy. Caspase 8 / genetics. DNA (Cytosine-5-)-Methyltransferase / physiology. Liver Neoplasms / drug therapy. Receptors, TNF-Related Apoptosis-Inducing Ligand / genetics. TNF-Related Apoptosis-Inducing Ligand / pharmacology
  • [MeSH-minor] Cell Line, Tumor. DNA Methylation. Drug Resistance, Neoplasm. Gene Silencing. Humans. Mitochondrial Proteins / metabolism. Promoter Regions, Genetic. RNA, Small Interfering / genetics. Up-Regulation

  • MedlinePlus Health Information. consumer health - Liver Cancer.
  • COS Scholar Universe. author profiles.
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20398055.001).
  • [ISSN] 1349-7006
  • [Journal-full-title] Cancer science
  • [ISO-abbreviation] Cancer Sci.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GRAMD4 protein, human; 0 / Mitochondrial Proteins; 0 / RNA, Small Interfering; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / TNF-Related Apoptosis-Inducing Ligand; EC 2.1.1.37 / DNA (Cytosine-5-)-Methyltransferase; EC 2.1.1.37 / DNA (cytosine-5-)-methyltransferase 1; EC 2.1.1.37 / DNA methyltransferase 3B; EC 3.4.22.- / Caspase 8
  •  go-up   go-down


28. Kurita S, Mott JL, Almada LL, Bronk SF, Werneburg NW, Sun SY, Roberts LR, Fernandez-Zapico ME, Gores GJ: GLI3-dependent repression of DR4 mediates hedgehog antagonism of TRAIL-induced apoptosis. Oncogene; 2010 Aug 26;29(34):4848-58

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) induces apoptosis through its cognate receptors death receptor 4 (DR4) and death receptor 5 (DR5), preferentially in malignant cells.
  • However, many malignant cells remain resistant to TRAIL cytotoxicity by poorly characterized mechanisms.
  • Blockade of Hh using pharmacological and genetic tools sensitizes the cells to TRAIL cytotoxicity.
  • Finally, small interfering RNA (siRNA)-targeted knockdown of GLI3, but not GLI1 or GLI2, restores DR4 expression and TRAIL sensitivity, indicating that the Hh effect is exclusively mediated by this transcription factor.
  • In conclusion, these data provide evidence of a regulatory mechanism, which modulates TRAIL signaling in cancer cells and suggest new therapeutic approaches for TRAIL-resistant neoplasms.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Nature. 2000 Aug 31;406(6799):1005-9 [10984056.001]
  • [Cites] N Engl J Med. 2009 Sep 17;361(12):1173-8 [19726761.001]
  • [Cites] J Cell Physiol. 2001 Jul;188(1):98-105 [11382926.001]
  • [Cites] Leukemia. 2001 Jul;15(7):1022-32 [11455969.001]
  • [Cites] J Biol Chem. 2001 Oct 19;276(42):38610-8 [11507096.001]
  • [Cites] Oncogene. 2002 May 9;21(20):3121-9 [12082627.001]
  • [Cites] Genes Dev. 2002 Nov 1;16(21):2743-8 [12414725.001]
  • [Cites] Nature. 2003 Oct 23;425(6960):846-51 [14520411.001]
  • [Cites] J Biol Chem. 2004 Jan 9;279(2):1197-205 [14555646.001]
  • [Cites] Cancer Res. 2004 May 15;64(10):3517-24 [15150106.001]
  • [Cites] EMBO J. 1995 Nov 15;14(22):5579-88 [8521815.001]
  • [Cites] Cell. 1996 Jul 12;86(1):147-57 [8689682.001]
  • [Cites] Science. 1997 Feb 21;275(5303):1132-6 [9027315.001]
  • [Cites] Development. 1997 Apr;124(7):1313-22 [9118802.001]
  • [Cites] Nature. 1998 Jan 1;391(6662):90-2 [9422511.001]
  • [Cites] Curr Opin Cell Biol. 1999 Apr;11(2):255-60 [10209153.001]
  • [Cites] Cancer Res. 2004 Nov 1;64(21):7724-31 [15520176.001]
  • [Cites] Gastroenterology. 2005 Jun;128(7):2054-65 [15940637.001]
  • [Cites] Gastroenterology. 2005 Nov;129(5):1696-710 [16285967.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2006 Jan;290(1):G129-36 [16166346.001]
  • [Cites] J Pharmacol Exp Ther. 2006 Dec;319(3):1153-61 [16982703.001]
  • [Cites] Nat Rev Drug Discov. 2006 Dec;5(12):1026-33 [17139287.001]
  • [Cites] Gastroenterology. 2007 Jan;132(1):384-96 [17241887.001]
  • [Cites] Int J Biochem Cell Biol. 2007;39(7-8):1462-75 [17403612.001]
  • [Cites] Nat Med. 2007 Sep;13(9):1070-7 [17767167.001]
  • [Cites] Oncogene. 2007 Sep 13;26(42):6133-40 [17404574.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2008 Feb;294(2):G363-7 [18063705.001]
  • [Cites] Apoptosis. 2008 Jun;13(6):756-70 [18421578.001]
  • [Cites] Oncogene. 2008 Jun 19;27(27):3856-64 [18264131.001]
  • [Cites] Nat Rev Cancer. 2008 Oct;8(10):782-98 [18813321.001]
  • [Cites] Gastroenterology. 2009 Jun;136(7):2365-2376.e1-7 [19272388.001]
  • [Cites] Genes Dev. 2009 Aug 15;23(16):1910-28 [19684112.001]
  • [Cites] Cancer Res. 2001 Feb 15;61(4):1314-9 [11245427.001]
  • (PMID = 20562908.001).
  • [ISSN] 1476-5594
  • [Journal-full-title] Oncogene
  • [ISO-abbreviation] Oncogene
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / R01 CA136526; United States / NCI NIH HHS / CA / P50 CA102701-08; United States / NIDDK NIH HHS / DK / P30 DK084567-01; United States / NIDDK NIH HHS / DK / R01 DK059427; United States / NIDDK NIH HHS / DK / P30 DK 84567; United States / NCI NIH HHS / CA / R01 CA100882; United States / NIDDK NIH HHS / DK / R56 DK059427; United States / NIDDK NIH HHS / DK / R01 DK059427-09; United States / NIDDK NIH HHS / DK / K01 DK079875-03; United States / NCI NIH HHS / CA / P50 CA102701; United States / NIDDK NIH HHS / DK / K01 DK079875; United States / NIDDK NIH HHS / DK / P30 DK084567; United States / NCI NIH HHS / CA / R01 CA100882-05; United States / NCI NIH HHS / CA / R01 CA136526-01; United States / NCI NIH HHS / CA / R56 CA100882; United States / NIDDK NIH HHS / DK / R01 DK59427
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / GLI3 protein, human; 0 / Hedgehog Proteins; 0 / Kruppel-Like Transcription Factors; 0 / Nerve Tissue Proteins; 0 / RNA, Small Interfering; 0 / Receptors, TNF-Related Apoptosis-Inducing Ligand; 0 / Receptors, Tumor Necrosis Factor; 0 / TNF-Related Apoptosis-Inducing Ligand; 0 / TNFRSF10A protein, human
  • [Other-IDs] NLM/ NIHMS216797; NLM/ PMC2928864
  •  go-up   go-down


29. Yegüez JF, Martinez SA, Sands DR, Sands LR, Hellinger MD: Colorectal malignancies in HIV-positive patients. Am Surg; 2003 Nov;69(11):981-7
HIV InSite. treatment guidelines - Human Herpesvirus-8 .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Due to the development of more effective medications, those infected with HIV are living longer.
  • A retrospective review of HIV/AIDS patients with colorectal malignant tumors was undertaken.
  • We included adult patients, with ELISA and Western blot test positive for HIV, and primary malignant tumors located in the colon or rectum.
  • Malignant neoplasms of the anus were excluded for the purposes of this study.
  • Twelve patients (9 males and 3 females), mean age 41 years, were identified with the following neoplasm: 6 adenocarcinomas (ACA), 5 non-Hodgkin lymphomas (NHL), and 1 small-cell carcinoma.
  • Intravenous drug abuse was the main risk factor for HIV.
  • No patient had identified risk factors for colorectal neoplasm.
  • Five out of six patients with ACA had metastatic disease at the time of diagnosis.
  • One patient with stage II ACA developed early liver metastases after colonic resection.
  • These patients developed tumors at earlier ages and were diagnosed at an advanced stage.
  • The use of the new antiretroviral therapy regimens should be further evaluated to know its impact in the survival.


30. Ocker M, Neureiter D, Lueders M, Zopf S, Ganslmayer M, Hahn EG, Herold C, Schuppan D: Variants of bcl-2 specific siRNA for silencing antiapoptotic bcl-2 in pancreatic cancer. Gut; 2005 Sep;54(9):1298-308
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND AND AIMS: Pancreatic cancer remains a devastating diagnosis with only limited therapeutic options.
  • Specific inhibition of expression of target genes has become possible using small interfering (si) RNAs.
  • We therefore investigated how far siRNA specific for bcl-2 may serve as a therapeutic option for pancreatic cancer in vitro and in vivo.
  • Cell survival and apoptosis were quantified at 24-120 hours.
  • Antiproliferative and proapoptotic effects were observed in tumour cells but not in fibroblasts or non-malignant tissues. siRNA permutations and diverse overhangs influenced gene silencing efficacy. siRNA was quickly distributed to all organs and excreted via the kidney and liver.
  • Bcl-2 specific siRNA is a promising adjunctive treatment for pancreatic carcinoma.
  • [MeSH-major] Gene Silencing. Genes, bcl-2. Genetic Therapy / methods. Pancreatic Neoplasms / therapy. RNA, Small Interfering / therapeutic use. Transfection / methods
  • [MeSH-minor] 3' Untranslated Regions. 5' Untranslated Regions. Animals. Apoptosis / genetics. Blotting, Western. Cell Line, Tumor. Cells, Cultured. Humans. Kidney / metabolism. Liver / metabolism. Male. Mice. Mice, Nude. Neoplasm Transplantation. Polymerase Chain Reaction / methods. Transplantation, Heterologous

  • Genetic Alliance. consumer health - Pancreatic cancer.
  • Genetic Alliance. consumer health - Pancreatic cancer 2.
  • MedlinePlus Health Information. consumer health - Genes and Gene Therapy.
  • MedlinePlus Health Information. consumer health - Pancreatic Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Cancer. 2003 Nov 10;107(3):453-9 [14506747.001]
  • [Cites] Antisense Nucleic Acid Drug Dev. 2003 Apr;13(2):83-105 [12804036.001]
  • [Cites] J Exp Ther Oncol. 2003 Jul-Aug;3(4):194-204 [14567290.001]
  • [Cites] Cell. 2003 Oct 17;115(2):199-208 [14567917.001]
  • [Cites] Acta Oncol. 2002;41(7-8):582-95 [14651201.001]
  • [Cites] RNA. 2004 Jan;10(1):12-8 [14681580.001]
  • [Cites] Ann N Y Acad Sci. 2003 Dec;1002:90-4 [14751826.001]
  • [Cites] Nucleic Acids Res. 2004;32(3):936-48 [14769950.001]
  • [Cites] Proc Natl Acad Sci U S A. 2004 Feb 17;101(7):1892-7 [14769924.001]
  • [Cites] Nat Biotechnol. 2004 Mar;22(3):326-30 [14758366.001]
  • [Cites] Cell. 1988 May 20;53(4):549-54 [2453289.001]
  • [Cites] Nature. 1990 Nov 22;348(6299):334-6 [2250705.001]
  • [Cites] J Pathol. 1992 Dec;168(4):357-63 [1484317.001]
  • [Cites] Am J Pathol. 1993 Aug;143(2):545-54 [8342602.001]
  • [Cites] Cell. 1993 Aug 27;74(4):597-608 [8358789.001]
  • [Cites] Gastroenterology. 1994 Jun;106(6):1645-51 [8194712.001]
  • [Cites] Ann Surg. 1995 Jan;221(1):59-66 [7826162.001]
  • [Cites] Nature. 1995 Apr 20;374(6524):733-6 [7715730.001]
  • [Cites] N Engl J Med. 1995 Oct 12;333(15):970-4 [7666916.001]
  • [Cites] Z Gastroenterol. 1997 May;35(5):319-26 [9265392.001]
  • [Cites] Nature. 1998 Feb 19;391(6669):806-11 [9486653.001]
  • [Cites] Oncology. 1999;56(1):73-82 [9885381.001]
  • [Cites] Aliment Pharmacol Ther. 2003 Nov;18 Suppl 3:7-30 [14531737.001]
  • [Cites] Gastroenterology. 1999 Dec;117(6):1464-84 [10579989.001]
  • [Cites] Br J Haematol. 1999 Dec;107(3):611-5 [10583267.001]
  • [Cites] Cell. 2000 Mar 31;101(1):25-33 [10778853.001]
  • [Cites] Trends Biochem Sci. 2000 May;25(5):241-6 [10782096.001]
  • [Cites] J Clin Oncol. 2000 May;18(9):1812-23 [10784621.001]
  • [Cites] Biochim Biophys Acta. 1999 Dec 10;1489(1):97-106 [10807000.001]
  • [Cites] Nature. 2000 Oct 12;407(6805):770-6 [11048727.001]
  • [Cites] Lancet. 2000 Nov 18;356(9243):1728-33 [11095261.001]
  • [Cites] Breast Cancer Res Treat. 2000 Oct;63(3):199-212 [11110054.001]
  • [Cites] Nature. 2001 Jan 18;409(6818):363-6 [11201747.001]
  • [Cites] Genes Dev. 2001 Jan 15;15(2):188-200 [11157775.001]
  • [Cites] Annu Rev Pharmacol Toxicol. 2001;41:403-19 [11264463.001]
  • [Cites] Nature. 2001 May 24;411(6836):494-8 [11373684.001]
  • [Cites] Dig Dis. 2001;19(1):6-14 [11385246.001]
  • [Cites] Semin Cancer Biol. 2001 Jun;11(3):201-18 [11407945.001]
  • [Cites] J Pathol. 2001 Aug;194(4):444-50 [11523052.001]
  • [Cites] Mech Ageing Dev. 2001 Oct;122(15):1695-706 [11557274.001]
  • [Cites] Oncogene. 2001 Sep 6;20(39):5466-74 [11571644.001]
  • [Cites] J Mol Med (Berl). 2001 Oct;79(10):587-93 [11692156.001]
  • [Cites] Nucleic Acids Res. 2002 May 1;30(9):1991-6 [11972337.001]
  • [Cites] Ann Oncol. 2002 Apr;13(4):539-45 [12056703.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Jun 24;100(13):7797-802 [12810955.001]
  • [Cites] Lung Cancer. 2003 Aug;41 Suppl 1:S81-8 [12867066.001]
  • [Cites] Nat Cell Biol. 2003 Sep;5(9):834-9 [12942087.001]
  • [Cites] Nature. 2002 Jul 4;418(6893):38-9 [12097900.001]
  • [Cites] Nature. 2002 Jul 11;418(6894):244-51 [12110901.001]
  • [Cites] Biochem Biophys Res Commun. 2002 Aug 30;296(4):1000-4 [12200148.001]
  • [Cites] Nat Rev Cancer. 2002 Sep;2(9):647-56 [12209154.001]
  • [Cites] Cell. 2002 Sep 6;110(5):563-74 [12230974.001]
  • [Cites] J Immunol. 2002 Nov 1;169(9):5196-201 [12391237.001]
  • [Cites] Cell. 2002 Nov 1;111(3):331-42 [12419244.001]
  • [Cites] Mol Immunol. 2003 Jan;39(11):615-47 [12493639.001]
  • [Cites] Blood. 2003 Feb 15;101(4):1566-9 [12393533.001]
  • [Cites] Nat Med. 2003 Mar;9(3):347-51 [12579197.001]
  • [Cites] Proc Natl Acad Sci U S A. 2003 Mar 4;100(5):2783-8 [12594341.001]
  • [Cites] J Mol Biol. 2003 Apr 4;327(4):761-6 [12654261.001]
  • [Cites] Eur J Biochem. 2003 Apr;270(8):1628-44 [12694176.001]
  • [Cites] Nucleic Acids Res. 2003 Jun 1;31(11):2705-16 [12771196.001]
  • [CommentIn] Gut. 2005 Sep;54(9):1215-6 [16099788.001]
  • (PMID = 16099798.001).
  • [ISSN] 0017-5749
  • [Journal-full-title] Gut
  • [ISO-abbreviation] Gut
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] England
  • [Chemical-registry-number] 0 / 3' Untranslated Regions; 0 / 5' Untranslated Regions; 0 / RNA, Small Interfering
  • [Other-IDs] NLM/ PMC1774673
  •  go-up   go-down


31. Haas BR, Sontheimer H: Inhibition of the Sodium-Potassium-Chloride Cotransporter Isoform-1 reduces glioma invasion. Cancer Res; 2010 Jul 1;70(13):5597-606
MedlinePlus Health Information. consumer health - Brain Tumors.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Malignant gliomas metastasize throughout the brain by infiltrative cell migration into peritumoral areas.
  • Invading cells undergo profound changes in cell shape and volume as they navigate extracellular spaces along blood vessels and white matter tracts.
  • Their efflux through ion channels along with obligated water causes rapid cell shrinkage.
  • NKCC1 localizes to the leading edge of invading processes, and pharmacologic inhibition using the loop diuretic bumetanide inhibits in vitro Transwell migration by 25% to 50%.
  • Short hairpin RNA knockdowns of NKCC1 yielded a similar inhibition and a loss of bumetanide-sensitive cell volume regulation.
  • A loss of NKCC1 function did not affect cell motility in two-dimensional assays lacking spatial constraints but manifested only when cells had to undergo volume changes during migration.
  • Intracranial implantation of human gliomas into severe combined immunodeficient mice showed a marked reduction in cell invasion when NKCC1 function was disrupted genetically or by twice daily injection of the Food and Drug Administration-approved NKCC1 inhibitor Bumex.
  • These data support the consideration of Bumex as adjuvant therapy for patients with high-grade gliomas.

  • Genetic Alliance. consumer health - Glioma.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2010 AACR.
  • [Cites] Neuron. 2000 Sep;27(3):447-59 [11055428.001]
  • [Cites] J Biol Chem. 2010 Apr 9;285(15):11188-96 [20139089.001]
  • [Cites] J Neurosci. 2001 Oct 1;21(19):7674-83 [11567057.001]
  • [Cites] J Neurosci. 2003 Jul 2;23(13):5572-82 [12843258.001]
  • [Cites] Mol Neurobiol. 2004 Feb;29(1):61-71 [15034223.001]
  • [Cites] Am J Physiol Cell Physiol. 2004 Jun;286(6):C1399-409 [14736709.001]
  • [Cites] Br Med J. 1972 Jan 22;1(5794):211-3 [4550872.001]
  • [Cites] Am J Physiol. 1984 May;246(5 Pt 1):C385-90 [6720936.001]
  • [Cites] Brain Res. 1987 Feb 24;404(1-2):1-9 [2436707.001]
  • [Cites] Eur J Biochem. 1988 Feb 1;171(3):425-33 [3345741.001]
  • [Cites] Mol Pharmacol. 1988 Jun;33(6):696-701 [3380083.001]
  • [Cites] Q J Exp Physiol. 1988 Mar;73(2):193-202 [3380935.001]
  • [Cites] J Biol Chem. 1996 Jul 5;271(27):16237-44 [8663127.001]
  • [Cites] Neurosurgery. 1996 Aug;39(2):235-50; discussion 250-2 [8832660.001]
  • [Cites] J Bioenerg Biomembr. 1998 Apr;30(2):161-72 [9672238.001]
  • [Cites] Cancer Res. 1998 Nov 1;58(21):4871-9 [9809993.001]
  • [Cites] J Gen Physiol. 1998 Nov;112(5):549-58 [9806964.001]
  • [Cites] J Neurosci. 1999 Jul 15;19(14):5942-54 [10407033.001]
  • [Cites] J Biol Chem. 1999 Sep 17;274(38):26946-55 [10480906.001]
  • [Cites] Neurol Res. 2005 Apr;27(3):280-6 [15845211.001]
  • [Cites] Am J Physiol Cell Physiol. 2005 Jun;288(6):C1451-60 [15659714.001]
  • [Cites] Semin Radiat Oncol. 2006 Apr;16(2):111-9 [16564446.001]
  • [Cites] J Biol Chem. 2006 Jul 14;281(28):19220-32 [16704974.001]
  • [Cites] Brain Res. 2007 May 4;1144:231-8 [17320059.001]
  • [Cites] J Exp Biol. 2007 Jun;210(Pt 12):2113-20 [17562884.001]
  • [Cites] Cell Physiol Biochem. 2007;20(1-4):121-30 [17595522.001]
  • [Cites] Cell Cycle. 2007 Jul 1;6(13):1613-20 [17581282.001]
  • [Cites] J Neurophysiol. 2007 Aug;98(2):786-93 [17581847.001]
  • [Cites] Cancer Res. 2007 Oct 1;67(19):9463-71 [17909056.001]
  • [Cites] J Natl Cancer Inst. 2007 Nov 7;99(21):1583-93 [17971532.001]
  • [Cites] Cell Prolif. 2008 Feb;41(1):98-121 [18211288.001]
  • [Cites] Biochem Pharmacol. 2008 May 1;75(9):1706-16 [18359479.001]
  • [Cites] Exp Biol Med (Maywood). 2008 Jul;233(7):779-91 [18445774.001]
  • [Cites] J Neurosci. 2008 Sep 10;28(37):9205-17 [18784301.001]
  • [Cites] Cell Prolif. 2008 Oct;41(5):775-85 [18823498.001]
  • [Cites] Biochem Pharmacol. 2009 Jan 15;77(2):159-68 [18992227.001]
  • [Cites] J Biol Chem. 2008 Dec 19;283(51):35539-50 [18957426.001]
  • [Cites] J Neurophysiol. 2009 Feb;101(2):750-7 [19036868.001]
  • [Cites] Neoplasma. 2009;56(3):224-9 [19309225.001]
  • [Cites] Glia. 2009 Jul;57(9):921-34 [19053055.001]
  • [Cites] Am J Physiol Gastrointest Liver Physiol. 2009 Jun;296(6):G1307-17 [19342507.001]
  • [Cites] Cancer Lett. 2010 May 28;291(2):158-66 [19906483.001]
  • [Cites] Neuroreport. 2001 Aug 8;12(11):2537-41 [11496144.001]
  • (PMID = 20570904.001).
  • [ISSN] 1538-7445
  • [Journal-full-title] Cancer research
  • [ISO-abbreviation] Cancer Res.
  • [Language] ENG
  • [Grant] United States / PHS HHS / / R01-031234; United States / NICHD NIH HHS / HD / P30 HD038985-08; United States / NINDS NIH HHS / NS / P30 NS057098; United States / NINDS NIH HHS / NS / R01 NS031234; United States / NINDS NIH HHS / NS / R01 NS031234-18; United States / NICHD NIH HHS / HD / P30 HD038985; United States / NINDS NIH HHS / NS / NS57098; United States / NICHD NIH HHS / HD / HD038985-08; United States / NINDS NIH HHS / NS / P30 NS057098-05; United States / NINDS NIH HHS / NS / NS036692-12; United States / PHS HHS / / R01-036692; United States / NINDS NIH HHS / NS / R01 NS036692; United States / NINDS NIH HHS / NS / R01 NS036692-12
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / RNA, Small Interfering; 0 / SLC12A2 protein, human; 0 / Slc12a2 protein, mouse; 0 / Sodium Potassium Chloride Symporter Inhibitors; 0 / Sodium-Potassium-Chloride Symporters; 0 / Solute Carrier Family 12, Member 2; 0Y2S3XUQ5H / Bumetanide
  • [Other-IDs] NLM/ NIHMS207208; NLM/ PMC2896443
  •  go-up   go-down


32. Goldstein MJ, Mitchell EP: Carcinoembryonic antigen in the staging and follow-up of patients with colorectal cancer. Cancer Invest; 2005;23(4):338-51
The Lens. Cited by Patents in .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • CEA is a complex glycoprotein produced by 90% of colorectal cancers and contributes to the malignant characteristics of a tumor.
  • Frequent monitoring of CEA postoperatively may allow identification of patients with metastatic disease for whom surgical resection or other localized therapy might be potentially beneficial.
  • To identify this group, serial CEA measurement appears to be more effective than clinical evaluation or any other diagnostic modality, although its sensitivity for detecting recurrent disease is not as high for locoregional or pulmonary metastases as it is for liver metastases.
  • Several studies have shown that a small percentage of patients followed postoperatively with CEA monitoring and who undergo CEA-directed salvage surgery for metastatic disease will be alive and disease-free 5 years after surgery.
  • Furthermore, CEA levels after salvage surgery do appear to predict survival in patients undergoing resection of liver or pulmonary metastases.
  • There is also no clear consensus on the frequency or duration of CEA monitoring, although the ASCO guidelines currently recommend every 2-3 months for at least 2 years after diagnosis.
  • In the follow-up of patients undergoing palliative therapy, the CEA level correlates well with response, and CEA is indicative of not only response but may also identify patients with stable disease for whom there is also a demonstrated benefit in survival and symptom relief with combination chemotherapy.
  • Immunotherapy based on CEA is a rapidly advancing area of clinical research demonstrating antibody and T-cell responses.
  • [MeSH-minor] Follow-Up Studies. Humans. Immunohistochemistry. Neoplasm Staging. Prognosis. Treatment Outcome

  • Genetic Alliance. consumer health - Colorectal Cancer.
  • MedlinePlus Health Information. consumer health - Colorectal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16100946.001).
  • [ISSN] 0735-7907
  • [Journal-full-title] Cancer investigation
  • [ISO-abbreviation] Cancer Invest.
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Biomarkers, Tumor; 0 / Carcinoembryonic Antigen
  • [Number-of-references] 181
  •  go-up   go-down






Advertisement